1. Introduction {#sec1}
===============

As the coronavirus disease 2019 (COVID-19) pandemic has spread widely around the globe ([@bib15]; [@bib18]), estimates about its eventual impact in terms of total number of deaths have varied widely, as they are mostly based on mathematical models with various speculative assumptions. It is crucial to estimate how much smaller the risk of death is among non-elderly people (\<65 years old) as opposed to older individuals and how frequent deaths are in people who are \<65 years old and have no underlying predisposing diseases. Media have capitalized on stories of young healthy individuals with severe, fatal outcomes. However, exaggeration should be avoided in responding to the pandemic ([@bib28]). Accurate estimates of mortality rate at different age groups have important implications. Deaths of young, healthy people contribute far more quality-adjusted life-years lost than deaths in elderly individuals with pre-existing morbidity. Knowledge of COVID-19 mortality rates for people \<65 years old at the population level can help guide different management strategies for the pandemic. People \<65 years old represent the lion\'s share of the workforce.

Here, we used data from 14 countries and 13 states in the USA that have been epicenters of the pandemic with a large number of deaths and where data were available for deaths according to age stratification. We aimed to evaluate the relative mortality rate in people \<65 years old versus older individuals in the general population, to provide estimates of absolute risk of COVID-19 death in these epicenters during the first epidemic wave, and to understand what proportion of COVID-19 deaths occur in people \<65 years old and without underlying diseases.

2. Methods {#sec2}
==========

We considered data from publicly reported situational reports of countries and US states or major cities that had already been major epicenters of the pandemic as of late April, 2020; thus epidemic waves are likely to be mostly completed almost two months later (by mid-June, 2020). Eligibility criteria included: (1) at least 800 deaths accumulated as of April 24, 2020 (so as to qualify for an early hotbed of the epidemic and to have a meaningful amount of data to analyze); and (2) information available on death counts per age strata, allowing to calculate numbers of deaths in people with age \<65 or, alternatively, at least in people with age \<60.

Different dates for extractions are listed throughout the manuscript, depending on data availability; [Supplementary Table 1](#appsec1){ref-type="sec"} provides all the dates of collection of the various COVID-19-related data.

For each of the eligible geographical locations, we extracted information from the most up-to-date situational reports as of May 23, 2020 (countries) or May 24, 2020 (US locations) focusing on total number of deaths with available age stratification, and number of deaths in age \<65 (or, if not available, number of deaths in age \<60 and in age 60--69), and ≥65. Information was extracted independently in duplicate by two authors (JI, CA) and discrepancies were resolved. Whenever information was unavailable for the desirable \<65 years cut-off, we contacted the respective authorities issuing the situational report. For secondary analyses, we also extracted information on deaths in the more granular age subgroups of \<40, 40--64, 65--79, and ≥80.

One author (DC-I) downloaded information on the proportion of the population in each eligible location for each age group. We used census information from populationpyramid.net/world/2019 for countries and from <https://worldpopulationreview.com> for the US states.

We calculated the population-level relative mortality rate of COVID-19 death for an individual \<65 years old as compared with an individual ≥65 years old for each eligible country and US state/city. This we calculated as the ratio of absolute risks (COVID-19 deaths with age \<65/population with age \<65 in the respective age-pyramid) divided by (COVID-19 deaths with age ≥65/population with age ≥65 in the respective age-pyramid). Inverting this relative mortality rate shows how many fold lower the risk of COVID-19 death is for an individual \<65 years old as compared with an individual ≥65 years old.

We also calculated the absolute risk of dying with COVID-19 during the first epidemic wave for a person \<65 years old in each eligible country and state by dividing the number of COVID-19 deaths (updated as of the end of day June 17, 2020) in this age group by the census population in this age group. Certainly, the number of deaths will increase and there is some uncertainty about the total projected number of deaths in each of these locations when this epidemic wave has passed, and all deaths have been counted. With the exception of India and Mexico, all other locations had largely completed the epidemic wave as of June 17 (for a visualization see [Supplementary Fig. 1](#appsec1){ref-type="sec"}) -- at least the first wave, since it remains unknown whether they may be any second waves. We also documented for each country and state the peak 7-day moving up to June 17, 2020. We used a 7-day moving frame, because there is some unavoidable noise fluctuation in death counts every day, plus for several countries and states there may be worse reporting delays for deaths during the weekend days. We used the actual date that deaths occurred for these estimates, but, whenever this was unavailable, we used the date of death reporting.

The magnitude of COVID-19 mortality rates is difficult to grasp, especially when population-level risks are small. Therefore, we converted the absolute risks of COVID-19 death into equivalents of mortality rate by a well-known, almost ubiquitous activity ([@bib27]), driving/travelling by motor vehicle. We used estimates from the International Transport Forum Road Safety Annual Report 2018 for the number of road deaths per billion vehicle miles driven for each European country ([@bib44]). For Spain, Italy, Portugal, and Mexico there were only data available for number of road fatalities per 100,000 inhabitants and for India we found similar data from Wikipedia. Since road deaths per 100,000 inhabitants tend to correlate reasonably well with road deaths per billion vehicle miles in Europe, we used for Italy and Portugal the same road deaths per billion miles as for Belgium, since Italy and Portugal have the same road deaths per 100,000 inhabitants as Belgium. Similarly, we used for Spain the same road deaths per billion miles as Germany. For Mexico and India, their road fatalities per 100,000 inhabitants were close to the USA values and we used the USA value road deaths per billion miles with adjustment for the difference. For USA locations, we used the state-specific data provided for 2018 by the Insurance Institute for Highway Safety ([@bib26]). In other words, for each location we identified the distance that one has to travel by motor vehicle to expose oneself to the same hazard as the absolute COVID-19 mortality rate observed until June 17, 2020. We then divided the estimated miles travelled by the number of days that have passed since the first COVID-19 death was recorded in each location and until June 17, 2020. The result transforms the average risk of COVID-19 death per day during the period where COVID-19 deaths occur into an equivalent of miles travelled by car per day. The longer the distance, the higher the risk. Of note, for a typical death curve, e.g. as documented in Wuhan ([@bib11]), the miles travelled per day estimate may be overestimated, if the covered fatality period extends beyond the peak of the curve (as is the case in all high-income locations that we analyzed), and may be underestimated otherwise -- this situation may apply to India and Mexico.

Finally, we sought information from the situational reports and from personal communications with the respective health authorities on how many COVID-19 deaths had been documented in people \<65 years old who had no underlying predisposing conditions. Predisposing conditions for worse outcome in COVID-19 may include ([@bib20]; [@bib64]; [@bib68]) cardiovascular disease, hypertension, diabetes, chronic obstructive pulmonary disease and severe asthma, kidney failure, severe liver disease, immunodeficiency, and malignancy. We followed the data collection principles of each national and state organization on how underlying conditions were defined. Data were readily available in published reports or public datasets for France ([@bib53]), Mexico ([@bib55]), Georgia ([@bib19]) and New York City ([@bib40]). We contacted all other national agencies and state departments of health when we could find contact information and thus we obtained additional such data according to the presence or not of underlying conditions from the Italian COVID-19 team (personal communication, Luigi Palmieri), from the Dutch COVID-19 team (personal communication, Susan van den Hof), and from the Swedish National Board of Health and Welfare (personal communication, Erik Wahlström) ([@bib58]). We encourage other organizations to send us similar data, as they become available, so that they can be incorporated in further updates. We avoided performing a formal meta-analysis, since these data are using different definitions of eligible comorbidities and data collection methods.

3. Results {#sec3}
==========

3.1. Eligible data {#sec3.1}
------------------

Eighteen countries (Belgium, Brazil, Canada, China, France, Germany, India, Iran, Ireland, Italy, Mexico, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom) and 13 US states (California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Massachusetts, Michigan, New Jersey, New York, Pennsylvania) fulfilled the first eligibility criterion and of those, 14 countries (Belgium, Canada, France, Germany, India, Ireland, Italy, Mexico, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom) as well as all 13 states had some available data on required age categories so that they could be included in our analysis. ([@bib53]; [@bib55]; [@bib19], [@bib54]; [@bib48]; [@bib51]; [@bib37]; [@bib22]; [@bib12]; [@bib50]; [@bib56]; [@bib7]; [@bib17]; [@bib4]; [@bib45]; [@bib59]; [@bib60]; [@bib16]; [@bib24]; [@bib25]; [@bib33]; [@bib34]; [@bib35]; [@bib61]; [@bib39]; [@bib41]; [@bib47])

3.2. Deaths with age stratification {#sec3.2}
-----------------------------------

Age distribution of COVID-19 deaths are shown in [Fig. 1](#fig1){ref-type="fig"} and detailed in [Table 1](#tbl1){ref-type="table"} (raw data in [Supplementary Table 2](#appsec1){ref-type="sec"}). Individuals with age \<65 accounted for only 4.5--11.2% of all COVID-19 deaths in all European countries and Canada. Among the 13 US locations, the proportion of deaths contributed by individuals \<65 ranged from 8.3 to 22.7% of all deaths. Conversely, in Mexico and India, they were the majority.Fig. 1Proportion of COVID-19 deaths by specific age group category. For detailed numbers, and deviations from age category cutoffs (when data were not provided for these exact age-categories), see [Table 1](#tbl1){ref-type="table"}.Fig. 1Table 1Proportion of COVID-19 deaths in specific age groups.Table 1Location (date report)Total deaths[a](#tbl1fna){ref-type="table-fn"}% of deaths age \<40 among total deaths% of deaths age 40--64 among total deaths% of deaths age 65--79 among total deaths% of age ≥80 among total deaths% of deathsage \<65 among total deaths*Countries*Belgium (May 22)65790.5[b](#tbl1fnb){ref-type="table-fn"}6.7[c](#tbl1fnc){ref-type="table-fn"}13.5[d](#tbl1fnd){ref-type="table-fn"}79.2[e](#tbl1fne){ref-type="table-fn"}7.2Canada (May 22)23050.63.9[f](#tbl1fnf){ref-type="table-fn"}26.3[g](#tbl1fng){ref-type="table-fn"}69.24.5France (May 18)174881.0[b](#tbl1fnb){ref-type="table-fn"}10.2[c](#tbl1fnc){ref-type="table-fn"}17.7[d](#tbl1fnd){ref-type="table-fn"}70.6[e](#tbl1fne){ref-type="table-fn"}11.2Germany (May 23)82110.44.2[f](#tbl1fnf){ref-type="table-fn"}31.3[g](#tbl1fng){ref-type="table-fn"}63.74.5 \[7.6\][h](#tbl1fnh){ref-type="table-fn"}India (May 21)343514.4[b](#tbl1fnb){ref-type="table-fn"}35.1[i](#tbl1fni){ref-type="table-fn"}NDND49.5[h](#tbl1fnh){ref-type="table-fn"}Ireland (May 20)13301.3[b](#tbl1fnb){ref-type="table-fn"}6.1[c](#tbl1fnc){ref-type="table-fn"}48.8[j](#tbl1fnj){ref-type="table-fn"}43.8[k](#tbl1fnk){ref-type="table-fn"}7.4Italy (May 20)310170.34.4[f](#tbl1fnf){ref-type="table-fn"}37.6[g](#tbl1fng){ref-type="table-fn"}57.73.6 \[7.1\][h](#tbl1fnh){ref-type="table-fn"}Mexico (May 24)73947.354.729.68.362.1Netherlands (May 22)57880.25.632.761.55.8Portugal (May 22)13020.14.2[f](#tbl1fnf){ref-type="table-fn"}28.2[g](#tbl1fng){ref-type="table-fn"}67.64.2 \[7.2\][h](#tbl1fnh){ref-type="table-fn"}Spain (May 22)205520.54.3[f](#tbl1fnf){ref-type="table-fn"}32.6[g](#tbl1fng){ref-type="table-fn"}62.74.7 \[7.7\][h](#tbl1fnh){ref-type="table-fn"}Sweden (May 22)39920.54.0[f](#tbl1fnf){ref-type="table-fn"}29.3[g](#tbl1fng){ref-type="table-fn"}66.14.5 \[6.9\][h](#tbl1fnh){ref-type="table-fn"}Switzerland (May 23)16400.32.4[f](#tbl1fnf){ref-type="table-fn"}27.7[g](#tbl1fng){ref-type="table-fn"}69.62.7 \[5.1\][h](#tbl1fnh){ref-type="table-fn"}UK (May 8)410201.1[b](#tbl1fnb){ref-type="table-fn"}10.1[c](#tbl1fnc){ref-type="table-fn"}15.4[d](#tbl1fnd){ref-type="table-fn"}73.4[e](#tbl1fne){ref-type="table-fn"}11.2*US locations*California (May 22)3708NDNDNDND21.0Connecticut (May 22)36740.75.6[f](#tbl1fnf){ref-type="table-fn"}34.2[g](#tbl1fng){ref-type="table-fn"}59.56.1 \[10.3\][h](#tbl1fnh){ref-type="table-fn"}Florida (May 24)23161.314.635.348.815.9Georgia (May 24)18212.320.538.638.722.7Illinois (May 24)48562.011.8[f](#tbl1fnf){ref-type="table-fn"}41.7[g](#tbl1fng){ref-type="table-fn"}44.413.9 \[19.8\][h](#tbl1fnh){ref-type="table-fn"}Indiana (May 23)18241.07.5[f](#tbl1fnf){ref-type="table-fn"}40.5[g](#tbl1fng){ref-type="table-fn"}50.98.5 \[13.8\][h](#tbl1fnh){ref-type="table-fn"}Louisiana (May 24)25672.212.7[f](#tbl1fnf){ref-type="table-fn"}NDND14.9 \[21.0\][h](#tbl1fnh){ref-type="table-fn"}Maryland (May 24)21032.09.8[f](#tbl1fnf){ref-type="table-fn"}41.5[g](#tbl1fng){ref-type="table-fn"}46.811.8 \[17.1\][h](#tbl1fnh){ref-type="table-fn"}Massachusetts (May 24)63720.44.5[f](#tbl1fnf){ref-type="table-fn"}32.5[g](#tbl1fng){ref-type="table-fn"}62.64.9 \[8.3\][h](#tbl1fnh){ref-type="table-fn"}Michigan (May 23)52282.011.0[f](#tbl1fnf){ref-type="table-fn"}45.0[g](#tbl1fng){ref-type="table-fn"}42.013.0 \[19.0\][h](#tbl1fnh){ref-type="table-fn"}New Jersey (May 22)11133NDND32.547.020.5New York (May 23)233821.813.1[f](#tbl1fnf){ref-type="table-fn"}45.7[g](#tbl1fng){ref-type="table-fn"}39.414.9 \[21.4\][h](#tbl1fnh){ref-type="table-fn"}Pennsylvania (May 21)49800.412.229.058.412.6[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12]

Individuals with age \<40 accounted for \<1.3% of all COVID-19 deaths in European countries and Canada and 0.4--2.3% in the US states, but were a much larger proportion in Mexico and India. Individuals 80 years or older accounted for the large majority of deaths (half to four-fifths or more) in Europe (except Ireland) and Canada, while in the US there was wider variability across states (range, 39--63%). In Mexico, they accounted for only 8.3% of deaths (no data on India).

3.3. Relative rate of dying with COVID-19 for individuals \<65 years old versus older individuals at the population level {#sec3.3}
-------------------------------------------------------------------------------------------------------------------------

As shown in [Fig. 2](#fig2){ref-type="fig"} (raw data in [Supplementary Tables 3--4](#appsec1){ref-type="sec"}), the percentage of the population \<65 years old varied from 75.18% to 86.31% in high-income countries' locations and exceeded 90% in India and Mexico. People \<65 years old had overall a 30- to 100-fold lower risk of COVID-19 death than those ≥65 years old in European countries and Canada, for the US locations, the relative mortality rate was somewhat smaller (16--52-fold), while for Mexico and India the relative mortality rate was less than 10-fold.Fig. 2Age distribution in the general population and relative mortality rate (relative risk of dying from COVID-19) for age ≥65 versus \<65. For India, the value in parenthesis is for the group \<60 years old, and relative mortality rate is given for ≥60 versus \<60 years.Fig. 2

3.4. Absolute risk of death with COVID-19 at the population level {#sec3.4}
-----------------------------------------------------------------

[Table 2](#tbl2){ref-type="table"} shows the estimates of the absolute risk of dying with COVID-19 at the population level for people \<65 years old and for those ≥80 years old as of June 17. For these estimates we used the total number of deaths as of the close of day June 17, 2020 (for sources see [Supplementary Table 5](#appsec1){ref-type="sec"}), and not just those where age information was available (as in [Table 1](#tbl1){ref-type="table"}). Also shown is the 7-day moving period that had the largest number of deaths. As shown, with the exception of India and Mexico, the peak period was already long before June 17, suggesting that the epidemic fatality waves had already reached substantial maturity as of June 17. Visual perusal ([Supplementary Fig. 1](#appsec1){ref-type="sec"}) also agrees that these epidemic waves are practically complete. The absolute risk of death for people \<65 years old in high-income countries ranged widely from 10 per million in Germany to 349 per million in New Jersey. Connecticut, Illinois, Louisiana, Massachusetts, Michigan, New Jersey, and New York had an absolute risk of death exceeding 100 per million. The risk was 5 per million in India (data on \<60 years old) and 96 per million in Mexico.Table 2COVID-19 deaths, peak 7-day period for deaths, population count and absolute risk of COVID-19 death for age groups \<65 (per million) and ≥80 (per thousand).Table 2LocationDay of first documented COVID-19 death[a](#tbl2fna){ref-type="table-fn"}Peak 7-day COVID-19 death count as of June 17Total COVID-19 deaths as of June 17 (n)[b](#tbl2fnb){ref-type="table-fn"}Risk for people \<65 (per million)Risk for people ≥80 (per thousand)*Countries*BelgiumMar 10Apr 7--13967575NDCanadaMar 9Apr 30-May 68213123.5FranceFeb 14Apr 2--82957564NDGermanyMar 9Apr 12--188830101.0IndiaMar 12June 11--17119035[c](#tbl2fnc){ref-type="table-fn"}NDIrelandMar 11Apr 19--25144925NDItalyFeb 22Mar 27-Apr 233168504.3MexicoMar 19June 3--918310960.8NetherlandsMar 6Mar 30-Apr 56074264.6PortugalMar 16Apr 7--131523141.5SpainFeb 13Mar 27-Apr 227136555.9SwedenMar 10Apr 9--155041446.4SwitzerlandMar 5Apr 2--81678122.6UKFeb 28Apr 7--134215386ND*US locations*CaliforniaFeb 6Apr 18--24520832NDConnecticutMar 17Apr 20--26421914517.5FloridaMar 6May 5--113018290.6GeorgiaMar 12Apr 16--222575651.4IllinoisMar 17May 5--1164851178.8IndianaMar 15Apr 21--272289563.3LouisianaMar 14Apr 5--112950155NDMarylandMar 17Apr 24--302866964.6MassachusettsMar 18Apr 18--24773411111.3MichiganMar 18Apr 10--1657921325.0New JerseyMar 11Apr 15--211276934914.2New YorkMar 14Apr 7--132462931914.6PennsylvaniaMar 18Apr 29-May 56319755.8[^13][^14][^15][^16]

The absolute risk of death for people ≥80 years old in high-income countries ranged from approximately 0.6 in a thousand in Florida to 17.5 in a thousand in Connecticut. For middle-income countries, it was 0.8 in a thousand in Mexico as of June 17 (no data for India).

[Table 3](#tbl3){ref-type="table"} shows the conversion of the absolute risk of COVID-19 death as of June 17 into the equivalent mortality rate from motor vehicle travelled miles. The distances (corresponding to equivalent mortality rates) ranged from driving a total of 416 miles to 47773 miles. Dividing by the number of days since the first documented COVID-19 death, the average daily risk of COVID-19 death for an individual \<65 years old in 11 of the 12 European countries or Canada is equivalent to driving between 12 and 82 miles per day during this period (94--126 days). California, Florida, Georgia, Indiana, and Pennsylvania are also in the same range of daily risk over 92--151 days. Conversely, the risk is higher in the UK and in the other 8 states in the USA (driving 106--483 miles per day) for the 92--111 days during which they have witnessed COVID-19 deaths. In India it was only 4 miles per day and in Mexico it was 79 miles per day.Table 3Absolute risk of COVID-19 death expressed as equivalent of mortality rate from associated with motor vehicle driving over given distances.Table 3LocationRoad deaths per billion miles\
TravelledRisk of COVID-19 death for \<65 year old people as total miles travelled equivalent until June 17Days with COVID-19 deaths (as of June 17)Risk of COVID-19 death for \<65 year old people as miles travelled per day equivalent*Countries*Belgium11.7638810064Canada8.2145310114France9.3688812555Germany6.8151110115India11.5[a](#tbl3fna){ref-type="table-fn"}416984[b](#tbl3fnb){ref-type="table-fn"}Ireland6.141799544Italy11.7[a](#tbl3fna){ref-type="table-fn"}430211537Mexico13.4[a](#tbl3fna){ref-type="table-fn"}71789179Netherlands7.6337510432Portugal11.7[a](#tbl3fna){ref-type="table-fn"}11719412Spain6.8[a](#tbl3fna){ref-type="table-fn"}814312665Sweden5.3821110082Switzerland5.1241710523UK5.515608111141*US locations*California10.2314615121Connecticut9.31563293168Florida14.1205710420Georgia11.457419859Illinois9.61223593132Indiana10.553399357Louisiana15.31015596106Maryland8.41139093122Massachusetts5.42060192224Michigan9.51388992151New Jersey7.34777399483New York7.64200796438Pennsylvania11.764499270[^17][^18]

3.5. COVID-19 deaths in individuals \<65 years old without underlying conditions {#sec3.5}
--------------------------------------------------------------------------------

Data on deaths in patients \<65 years old without any underlying conditions (comorbidities) were available for France, Italy, Mexico, Netherlands, Sweden, Georgia, and New York City. As shown in [Table 4](#tbl4){ref-type="table"} , the proportion of these deaths ranged from 0.7 to 3.6% of all COVID-19 deaths with the exception of Mexico that had a much higher percentage (17.7%). Excluding Mexico, the highest proportions were in France, Sweden, and Georgia. France data were based on deaths for which electronic death certificates were available, and completeness of death certificate information is unknown ([@bib53]). Data on Sweden were based on death counts that included also probable deaths without laboratory confirmation; moreover, only cardiovascular disease, hypertension, diabetes, and pulmonary disease were counted as comorbidities in this assessment, so it is possible that additional patients may have had other comorbidities ([@bib58]).Table 4COVID-19 deaths in individuals \<65 years old without underlying conditions.Table 4Location (date report)Deaths: total; age \<65 (n)Deaths assessed for comorbidities: total; age \<65 (n)Deaths with age \<65 without comorbidities (n)Percentage of deaths in age \<65 without comorbidities[a](#tbl4fna){ref-type="table-fn"}*Countries*France (June 23)29720; 208011071; 10713072.0%Italy (April 2)12550; 1135917; ND60.7%Mexico (June 26)25779; 1503525638; 14947453517.7%Netherlands (April 25)4409; 2572730; 204230.7%Sweden (June 24)5082; 3005082; 3001212.4%*US locations*Georgia (June 26)2770; 6092089; 4821143.6%New York City (June 26)17753; 468115694; 42151040.7%[^19][^20]

The lowest percentage (0.65% of all COVID-19 deaths) was seen in New York City. Similarly low percentages (0.7% of all COVID-19 deaths) were seen in Italy and Netherlands based on more detailed medical chart review. In Italy, this review is done on a subset of the deaths (n = 917 as of April 2). In the Netherlands, information on underlying diseases is sought since April 10th only for those who died \<70 years of age.

4. Discussion {#sec4}
=============

The evaluation of data from 14 countries and 13 US locations that are epicenters of the COVID-19 pandemic shows that non-elderly people \<65 years old represent a small fraction (4.5--11.2%) of all COVID-19 deaths in European countries and Canada and between 8.3% and 22.7% of all COVID-19 deaths in 13 US locations, even though this age group represents the majority of the general population. Conversely, in Mexico and India, most COVID-19 deaths occurred in the \<65 age group. Overall, the risk of death is 15-100-fold lower in non-elderly people \<65 years old than in older individuals in high-income countries and US states, but less than 10-fold lower in India and Mexico. The age-dependent risk gradient is modestly sharper in European countries and Canada versus most of the US locations. Regardless, the absolute risk of death in the non-elderly population is consistently very low even in these pandemic hotbeds. As of June 17, 2020, only 5 to 349 per million people in this age group have died with a COVID-19 diagnosis and the epidemic wave is practically complete in Europe and North America. Moreover, the vast majority of deaths in this age group occur in the age group 40--65 that comprises 37--48% of the population in the 0--65 years old bracket.

Unless there is a further peak of deaths downstream, the total risk of death for the entire epidemic wave in these locations may not be much larger than what has been documented as of June 17 (with the exception of Mexico and India), assuming a fairly symmetric epidemic wave, as in the case of Wuhan ([@bib68]). The risk observed in this first wave cannot be extrapolated to any future second wave, which is unknown whether it will exist and, if so, how high it might be.

For the whole COVID-19 fatality season to-date (starting with the date the first death was documented in each location), the average daily risk of dying from coronavirus for a person \<65 years old is equivalent to the risk of dying driving a distance of 4--82 miles by car per day during that COVID-19 fatality season in 18 of the 27 hotbeds and 106--483 miles per day in the other 9 hotbeds (UK and 8 USA locations). For many hotbeds, the risk of death is in the same level roughly as dying from a car accident during daily commute, although it can be higher in the locations that are most hit. For example, the average commute is 31.5 miles per day for Americans according to the American Driving Survey ([@bib31]) and 16.9 miles per day round trip in Sweden ([@bib63]). The highest daily risk of COVID-19 death (in New Jersey) corresponds roughly to the risk of dying in a traffic accident while travelling daily from Manhattan to Washington, DC round trip for these 99 days of COVID-19 fatalities-period. We provide raw data for diverse age groups (\<40, 40--65, 65--80, \>80), so that one can calculate risks in these age groups as well. People who are 40--65 years old may have about double the risk of the overall \<65 age stratum, while those 40 years old or younger have almost no risk at all of dying. Moreover, females may have approximately 2-times lower risk than males ([@bib66]).

These risk estimates correspond to the main epicenters of the pandemic that accounted for almost 300,000 of the COVID-19 deaths as of June 17, 2020 and (with the exception of India and Mexico) exceeded 100 deaths per million inhabitants. The majority of countries around the world and the majority of states and cities in the USA have much lower fatality rates; in these places, the risk of death from COVID-19 this season for people \<65 years old may typically be similar or even smaller to the risk of dying from a car accident during daily commute. We acknowledge that we cannot make any statement about the occurrence and magnitude of any second wave (e.g. in the fall/winter or next spring), but even for influenza the magnitude of the 2020--2021 wave is largely unpredictable.

The absolute mortality rate in an age group depends on the proportion of people infected and on the infection fatality rate in that age group. The proportion of people infected depends on the natural spread of the virus and the impact of preventive measures taken. The relative mortality rate between different age groups depends mostly on the difference in the infection fatality rate of these age groups and may also be modulated if preventive measures are taken that decrease exposure and spread in one age group more than in another. Most seroprevalence studies to-date suggest fairly similar rates of spread of the virus in different ae groups. But some exceptions may exist ([@bib29]).

We should acknowledge that the risk estimates presented in our analysis integrate the composite effects of all the measures taken by the authorities in each location. Population-level mortality rates would have been different if no measure to limit disease transmission was taken. Absolute risks may be shaped by these preventive measures, although we have no "control" data to see what the risk would have been if some of these measures had not been taken or if different measures had been adopted. It is also likely that in most of the examined epicenters most of the preventive measures (e.g. lockdowns) were probably implemented horizontally, in the whole population, without substantial differences between age groups. If so, the relative population-level mortality rates (comparing young with elderly) may be more stable than absolute risk estimates. Nevertheless if specific measures focus more on protecting specific age-groups (e.g. focusing more on specifically protecting the elderly in the future), mortality rates in different age groups may change by different amounts and this may thus affect also the relative mortality rate estimates.

We should also acknowledge that most of the epicenters considered in this analysis are high-income countries with generally high life expectancy. For lower-income countries, the proportion of deaths among younger age strata appears substantially larger. This may reflect differences in life expectancy and age pyramids. For example, in India, life expectancy is almost a decade less than in the USA and almost 15 years less than in Switzerland, making octogenarians and nonagenarians few in relative terms. The overall population level mortality rate across all age groups is much lower compared with the other epicenters we analyzed; thus the absolute population risk of death for non-elderly individuals in India is extremely low. For Mexico, the proportion of elderly people is higher than India but still very low (\<8% above 65).

Some caveats about the data need to be discussed. Even though mortality is an unambiguous endpoint, attribution of death to a specific cause is often challenging and definitions of "COVID-19 death" vary across countries and sometimes even change within countries over time. For example, the presented age-stratified data on Canada do not seem to include deaths that happened outside the hospitals. Different countries and US locations differ on the threshold of including deaths at care homes. For example, in Belgium, 53% of deaths come from care homes, but 94% of them have not had laboratory confirmation ([@bib49]). Several US locations have also started counting also "probable" deaths without any COVID-19 laboratory confirmation, a debatable practice at best. On the other hand, this may be defended as a justified approach since in some locations testing was not available or not performed. Overall, some COVID-19 deaths may be missed, and others may be overcounted. Different death tallies are derived by different sites, e.g. CDC ([@bib5]) and the popular Worldometer site. ([@bib69]) Arbitration and proper calibration of death counts may need to await careful, in depth medical chart review and autopsy efforts. Under- and over-counting may be responsible for some of the heterogeneity observed in risk estimates.

We should also acknowledge that we focused on mortality risk and not on hospitalizations. Empirical experience shows that COVID-19 has the potential to overwhelm specific hospitals (e.g. Lombardy, Queens or Bronx), especially in settings where hospitals run close to maximum capacity even under regular circumstances, and when they serve high risk populations in cities with high population density and major congregations in mass events. Therefore, hospital preparedness is essential, regardless of whether the risk of death is very low in the general population. Similarly, work modeling hospital bed needs is useful. However, for understanding the risk of individuals from the general population, the analogy against deaths by motor vehicle accidents is still relevant, since motor vehicle accidents also result in many more people who require hospitalizations and who suffer major injuries beyond the numbers of those who die.

The mortality rate estimates that we calculated may also be corroborated by the perusal of patterns of excess mortality in the general population during the period of COVID-19 fatalities. For example, data from 24 European countries ([@bib14]) show that in the 11 weeks between week 10 and week 21 in 2020, the excess of deaths increased by 13780 deaths in the \<65 years age category and by 152418 deaths in the older age category. Therefore, the excess deaths in the \<65 years category accounted for 8.3% of the total excess, a number very compatible with the 4.5--11.2% figure observed in the 11 European countries that we analyzed. However, one should be cautious in this comparison, because changes in other causes of deaths may also affect the magnitude of the overall excess during this period. In fact, there is concern that COVID-19 measures may have taken a toll on other causes of death, e.g. people with heart attacks may fear for coming to hospitals for treatment ([@bib32]; [@bib36]).

The large majority of the deaths in non-elderly individuals occur in patients who have underlying diseases. Based on existing data to-date ([@bib20]; [@bib64]; [@bib68]), cardiovascular disease, hypertension, chronic obstructive pulmonary disease and severe asthma, diabetes, kidney failure, severe liver disease, immunodeficiency, and malignancy may confer an increased risk of adverse outcome. Individuals with these diseases should consider that their risk may be higher than average and rigorous prognostic models need to be developed to estimate with accuracy this increased risk. In non-elderly populations, the more prevalent of these conditions is cardiovascular disease and hypertension, with prevalence of approximately 10% in the 20--39 age group and 38% in the 40--59 age group in the USA ([@bib70]) and similarly high percentages in many other countries. We encourage public health authorities to start reporting systematically data separately on each of the major comorbidities according to age strata. Some data are available for the prevalence of these conditions across all age groups of COVID-19 deaths. Data from the UK from the OpenSafely study suggest that hypertension alone does not increase the risk of death, while uncontrolled diabetes, controlled diabetes, severe asthma, and chronic heart disease increases the risk 2.36-, 1.50-, 1.27- and 1.25 -fold ([@bib66]).

We could retrieve data from 7 locations on the COVID-19 mortality of people who were both \<65 years old and had no underlying diseases. Consistently, the data suggest that these deaths are remarkably uncommon in high-income countries, although their exact percentage contribution to all COVID-19 deaths varies modestly across locations (0.7--3.6%). It is likely that much of this variability may reflect differences on how underlying conditions are captured. We also caution that some people with no recorded comorbidities may have had some underlying diseases, but these where not reported in a crisis setting, or these conditions may have been undiagnosed. Overall, this further strengthens the notion that for healthy non-elderly people, the risk of dying from COVID-19 in the first half of 2020 was very small. This is in stark contrast with many news stories that focus on the demise of young people and the panic and horror that these widely reverberated stories are causing ([@bib23]; [@bib43]). Conversely, the available data from Mexico suggest that one out of six deaths were in people \<65 and without underlying conditions ([@bib55]). This may primarily reflect a different age-pyramid, although additional reasons might be deleterious effects of deprivation, lower access to health services, or higher rates of undiagnosed conditions in lower-income countries. It is very important for authorities in all countries and US locations to report carefully curated data on comorbidities and related death rates.

Another interesting observation is the higher share of deaths in the \<65 years old group in most of the US locations as opposed to the European countries. This pattern requires further investigation, but it may reflect unfavorable socioeconomic circumstances for victims of COVID-19 in the USA. It is important to study in more detail the socioeconomic profile of the COVID-19 victims, but preliminary data show that deaths cluster in areas with high levels of poverty and underprivileged populations and ethnic/racial minorities are over-represented among the victims ([@bib6]). Some mostly low-wage occupations, including essential jobs, also may be prone to more exposure risk than other jobs where working remotely is feasible. COVID-19 may thus be yet another disease with a profile dependent on inequalities and generating even more inequalities. The difference in the proportion of deaths in people \<65 years old across different US locations may be due to chance, or may reflect genuine differences in the proportion of deaths occurring in nursing homes and/or the proportion of deaths occurring in younger populations of disadvantaged people, differences in reporting of COVID-19 deaths, or other unclear reasons. Of interest, influenza deaths seem to have a similar difference in age distribution between the USA and European countries like Italy: a larger proportion of influenza deaths in the USA tend to be in the \<65 age group ([@bib13]), as compared with Italy ([@bib52]). Of course, a major difference between influenza and COVID-19 is that the latter typically does not cause deaths in otherwise healthy children, in contrast to influenza ([@bib65]).

The vast majority of COVID-19 victims are elderly people and in all European countries analyzed as well as Canada and most US locations, more than half and up to three quarters are at least 80 years old. The median age of death for COVID-19 tends to be similar or slightly smaller than the life expectancy of the population in each respective location. In several locations, large clusters of deaths come from nursing home facilities. Data from European countries suggest that 42--57% of all deaths have happened in care homes ([@bib3]) and many deaths in the US have also occurred in nursing homes ([@bib42]). Moreover, the differentiation between dying "with" SARS-CoV-2 versus dying "from" SARS-CoV-2 may be difficult to make, and the vast majority of patients with COVID-19 have comorbidities and these could also contribute to the fatal outcome or may be even more important than SARS-CoV-2 in causing the death ([@bib2]). Nursing homes and hospitalized patients (nosocomial infection) appear to account for a lion\'s share of COVID-19 mortality. Overall, the loss of quality-adjusted life-years from COVID-19 may be much smaller than a crude reading of the number of deaths might suggest, once these features are accounted for.

The data that we have compiled allow to estimate also absolute risks of death in the highest risk group, i.e. elderly individuals ≥80 years old in these hot epicenters of the pandemic. These are markedly higher than the risks of death in individuals \<65 years old. However, the absolute risk of death even in this highest age category to-date barely reach up to 1.75% in the most hit location and in several locations it is lower than 1 in a thousand. Nevertheless, these risks are clearly high enough to warrant high alert. They suggest that, no matter what strategy is selected for addressing COVID-19 in the current or future epidemic waves should include special emphasis in protecting very elderly individuals.

Knowledge of relative and absolute risks for different population strata are instrumental for carefully choosing next steps. Lockdowns have been implemented in many countries and this was a fully justified initial "better safe than sorry" approach in the absence of good data. However, long-term lockdowns may have major adverse consequences for health (suicides, domestic violence, worsening mental health, cardiovascular disease, loss of health insurance from unemployment, and famine, to name a few) and also creating new major issues for society at large ([@bib32]; [@bib8]; [@bib10]; [@bib62]; [@bib38]; [@bib46]). Lockdowns originally aimed to save the health care system, but as patients avoid coming to the hospitals for common, treatable problems ([@bib9]), deaths may rise from non-treatment; also hospitals face an emerging crisis also leading to their demise. It is even argued that lockdowns may be even harmful as a response to COVID-19 itself, if they broaden rather than flatten the epidemic curve ([@bib67]). Information from seroprevalence and universal screening studies suggest that the frequency of infections is much larger than the documented cases and thus the overall infection fatality rate is likely to be much lower than previously thought ([@bib29]; [@bib1]; [@bib57]; [@bib30]). It seems that the majority of infections are either asymptomatic or mildly symptomatic and thus do not come to medical attention ([@bib21]). These data also suggest that the infection fatality rate may be close to that of a severe influenza season (\<0.2%) when the health system does not collapse and when massive nosocomial infections and nursing home spread are averted. Conversely, high infection fatality rates are seen when hospitals are overrun, and when there are massive death loads from nosocomial-infected hospitalized patients and nursing home residents. Therefore, the finding of very low risk in the vast majority of the general population has major implications for strategic next steps in managing the COVID-19 pandemic. Tailored measures that maintain social life and the economy functional to avoid potentially even deaths from socioeconomic disruption, plus effective protection of select high-risk individuals (in particular in hospitals and nursing homes) may be a sensible option. Draconian measures of hygiene and infection control and universal, repeated testing of personnel in hospital and care facilities may achieve drastic reductions in deaths. Concurrently, the vast majority of the population may be reassured that their risks are very low.
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[^1]: The proportions of deaths across different categories may change if late-occurring or late-reported deaths have a different age distribution. This may be an issue specifically for Mexico and India where the epidemic wave was still far from mature at the time of data collection. As of June 26, 2020, no updated age-group death data could be found for India, but such updated data were available for Mexico, and the age distribution had not changed much, e.g. 58.3% of deaths were in people with age \<65 years. ND: no data.

[^2]: Using deaths\' data with available information on age.

[^3]: Group \<45 years (not available for \<40 years).

[^4]: Group 45--64 years (not available for 40--64 years).

[^5]: Group 65--74 years (not available for 65--79 years).

[^6]: Group ≥75 years (not available for ≥80 years).

[^7]: Group 40--59 years (not available for 45--64 years).

[^8]: Group 60--79 years (not available for 65--79 years).

[^9]: Group \<60 years \[the number shown in brackets is the approximated estimate for age \<65 assuming that a third of the deaths in the 60--69 bracket are in \<65 years old people, as suggested by other countries where data are available on 5-year age intervals\].

[^10]: Group 45--59 years (not available for 45--64 years).

[^11]: Group 65--84 years (not available for 65--79 years).

[^12]: Group ≥85 years (not available for ≥80 years).

[^13]: Peak 7-day period of deaths is based on data as of June 17 (June 14 for Ireland and June 15 for Italy) and thus higher peaks and/or a second wave cannot be fully excluded. For France, Germany, Ireland, Italy, Portugal, Spain, Michigan, New Jersey, and New York only date of deaths reported were available, not actual date of death. ND: no data to allow calculation.

[^14]: Based on official reports or news articles, but cannot exclude earlier COVID-19 deaths that went undetected.

[^15]: Sources for total death counts are available in [Supplementary Table 5](#appsec1){ref-type="sec"}.

[^16]: For India: risk for people \<60 years (per million) since \<65 was not available.

[^17]: Approximation (see Methods, we welcome provision of any more precise estimates).

[^18]: For India: risk for people \<60 years since \<65 was not available.

[^19]: ND: no data available.

[^20]: In the estimation, it is assumed that among deaths in patients \<65, the presence of comorbidities is equally frequent in the patients whose medical records have not been assessed and in those whose medical records have been assessed.
